Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
21 août 2024 08h45 HE
|
Oragenics
• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients • No pharmaceutical treatment is available for...
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
16 août 2024 16h30 HE
|
Oragenics
SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of...
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
12 août 2024 08h30 HE
|
Oragenics
– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on...
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
10 juil. 2024 08h00 HE
|
Oragenics
SARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
27 juin 2024 08h30 HE
|
Oragenics
SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics, Inc. Announces Closing of Public Offering
26 juin 2024 16h47 HE
|
Oragenics
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics, Inc. Announces Proposed Public Offering
24 juin 2024 18h43 HE
|
Oragenics
SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of...
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
20 juin 2024 08h00 HE
|
Oragenics
SARASOTA, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
22 mai 2024 08h00 HE
|
Oragenics
SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
17 mai 2024 08h00 HE
|
Oragenics
SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today...